Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
182
resultados
Última actualización
16/01/2026 [07:23:00]
Resultados 100 a 125 de 182
Resumen de: US2025277269A1
This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.
Resumen de: WO2025181330A1
The present disclosure relates to dosage regimens for glucagon-like-peptide-2 (GLP-2) analogs, e.g., apraglutide, in a subject in need thereof, e.g., a subject with short bowel syndrome (SBS).
Resumen de: WO2025184435A1
The present invention provides an improved breath analyzer and breath test method to determine the presence of disease in humans, including but not limited to, H. pylori infection, Celiac Disease, Metabolic dysfunction-associated steatohepatitis (MAHD), Inflammatory Bowel Disease (JBD). 'm a subject's digestive tract. In certain embodiments, the present invention provides a universal breath testing platform and methods of testing for diseases of the gastrointestinal tract, the liver, the kidneys, and the lungs, along with testing for cancer, infections, and metabolic diseases.
Resumen de: EP4610657A1
Provided are a method for detecting an immune-mediated inflammatory disease characterized by an increase in expression of MMP12, in a subject, a diagnostic drug containing a substance that specifically interacts with MMP12, and a therapeutic agent containing an MMP12 inhibitory substance.
Resumen de: US2025243548A1
Described herein are methods and compositions related to the discovery of associations in TNFSF15 15 and DcR3 genetic loci across in Caucasian, Puerto Rican, and Korean Crohn's Disease, as demonstrated via trans-ethnic fine mapping. The present invention provides methods of quantifying risk and diagnosing susceptibility to Crohn's disease in a subject by determining the presence of one or more risk variants are at the TNFSF15 (or TL1A) and/or DcR3 genetic loci.
Resumen de: CN120577530A
The invention discloses a therapeutic target for inflammatory bowel disease and application thereof. Research finds that NO can be combined with an enzyme active site of a CYP450 family member, so that the activity of the CYP450 family member is inhibited, finally generation of a pathogenic factor GM-CSF is inhibited, and enteritis is relieved. On the basis, an inflammatory bowel disease product, a kit and an analysis system are developed. According to the invention, a new strategy can be provided for preventing, detecting and treating intestinal inflammatory diseases, and the intestinal homeostasis imbalance can be effectively improved.
Resumen de: MX2025009868A
The present disclosure generally relates to methods, and diagnostic applications, for the treatment of ulcerative colitis. More particularly the methods and diagnostic applications of the present invention relate to expression profiles of certain gene transcripts in ulcerative colitis patients and the usefulness of the expression profiles of these gene transcripts for the treatment, and/or diagnostic use in a subgroup of patients having ulcerative colitis.
Resumen de: AU2024213250A1
The present disclosure provides compositions and methods for using stool-derived, eukaryotic, nucleic acid biomarkers to diagnose disease, assess disease activity, monitor mucosal healing, and predict therapeutic response. The described biomarkers can be used by practitioners to better diagnose, manage, and treat inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD).
Resumen de: CN120549942A
According to the application, the application of the taurocholic acid (TCA) in the medicine for preventing and treating the colitis injury is found and proved, the clinical effect is remarkable, the TCA with a proper concentration can promote the growth of Caco-2 cells and can relieve inflammation caused by LPS, but the TCA with a high concentration can inhibit the growth of the Caco-2 cells. Through intragastric administration of TCA, mouse colitis induced by escherichia coli can be relieved, TCA with a proper concentration can treat colitis, and through in-vitro and in-vivo dual verification, the optimal concentration of TCA in the aspect of treating colitis and the treatment effect of TCA on colitis caused by pathogenic escherichia coli are determined. Theoretical support is provided for medicine development of TCA in the aspect of treating intestinal inflammation, and the TCA is worthy of being widely popularized and used clinically.
Resumen de: CN120555244A
The invention discloses pathogenic escherichia coli which is named as Escherichia coli.NM3A and is preserved in China Center for Type Culture Collection on April 14, 2025, the preservation address is No.3, No.1 yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC No: 34176. According to the invention, a mouse colitis model can be established by using the calf-derived Escherichia coli.NM3A, and the new Escherichia coli.NM3A separated from calf feces can be proved to have a pathogenic gene through whole genome sequencing and virulence gene PCR (Polymerase Chain Reaction) detection; a mouse inflammation model is established by feeding the Escherichia coli.NM3A into the calf excrement, and the new Escherichia coli.NM3A separated from the calf excrement can be proved to have pathogenicity and can cause mouse colitis.
Resumen de: CN120559221A
The invention discloses application of Gli1 + interstitial cells or SMOC2 protein thereof in diagnosis, treatment and prognosis evaluation of Crohn disease intestinal stenosis. The invention provides application of Gli1 + interstitial cells and SMOC2 protein as targets in preparation of a diagnostic kit or a therapeutic drug for Crohn disease fibrostenosis, and further provides the diagnostic kit for Crohn disease fibrostenosis and the therapeutic drug for Crohn disease fibrostenosis. Meanwhile, the invention further provides application of the reagent for detecting the expression quantity of the SMOC2 in preparation of the kit for evaluating postoperative recurrence of the Crohn disease fibrostenosis and the corresponding kit for evaluating postoperative recurrence of the Crohn disease fibrostenosis. The invention discusses the effect of the Gli1 + interstitial cells in the attack of intestinal fibrostenosis, evaluates the potential of the Gli1 + interstitial cells as a diagnosis and treatment target, and provides a new thought for the treatment of Crohn disease intestinal stenosis.
Resumen de: CN120554525A
The invention provides a fusion protein as well as a preparation method and application thereof. Specifically, the fusion protein disclosed by the invention has a structure as shown in a formula I: in the formula, Z0 is a tag sequence for purposes of purification, separation and the like; z1 is a human serum amyloid A protein fragment; l1 is none or a joint; z2 is fluorescent protein. The invention provides a preparation method and application of the fusion protein, the method is high in yield and free of risks of cross infection, gene mutation and the like, and the Clover-SSA1 protein prepared through the method can be used in the research fields of disease diagnosis, drug screening, biomarkers and the like, namely Z0-Z1-L1-Z2 (I).
Resumen de: CN120550120A
The invention discloses an application of inhibiting CD4 + T cell aging in preparation of a medicine for slowing down the progress of elderly ulcerative colitis. The invention provides an application of a substance for inhibiting the aging of CD4 + T cells in preparation of a product with at least one of the following functions: preventing senile ulcerative colitis; treating the elderly ulcerative colitis; the progress of elderly ulcerative colitis is relieved; diseases caused by aging of CD4 + T cells can be prevented or treated. A mouse model of specific knockout of the CD4 + T cell METTL3 is constructed, and it is found that specific knockout of the CD4 + T cell METTL3 can significantly inhibit the aging phenotype of the CD4 + T cell, so that DSS-induced mouse colitis and T cell adoptive transfer mediated enteritis are relieved. By improving CD4 + T cell senescence, UC, especially the progress of elderly UC, is relieved.
Resumen de: WO2025177282A1
A system for predicting a response to nutritional therapy for treating Crohn's Disease (CD), including a computer with a processor and memory, a machine learning module, wherein the machine learning module is programed to train a model by accepting a training data set comprising multiomics data of subjects with Crohn's disease that were treated by exclusive enteral nutrition (EEN) and a determination if each subject was a responder that successfully responded to the treatment or was a non-responder that unsuccessfully responded to the treatment, and wherein the machine learning module uses the trained model to accept multiomics data of a patient and predict if the patient is a responder or a non-responder.
Resumen de: WO2025176817A1
The present invention relates to diagnostic and prognostic methods and their use in diagnosing or predicting disease progression in a subject with Ulcerative Colitis (UC). More particularly, the present invention relates to a gene expression signature and the use thereof in determining the likelihood of progression of Ulcerative Colitis in a subject, as well as compositions for the detection thereof. The invention also extends to the use of biomarkers as targets to improve the treatment of Ulcerative Colitis in patients.
Resumen de: WO2025176879A1
The present invention relates to methods of immunoassay for detecting or monitoring inflammatory bowel disease or a severity thereof in a patient. In certain embodiments, the inflammatory bowel disease may be ulcerative colitis.
Resumen de: US2025271429A1
A system or method for a combination assay of human antibodies to Mycobacterium avium subsp. paratuberculosis (MAP) and cytokines for the diagnosis of Crohn's disease, tuberculosis, and other bacterial diseases in symptomatic and asymptomatic individuals is provided herein. The system or method describes generally using a combination of human antibodies to MAP useful for the detection of a MAP infection in human blood samples and cytokines secreted by the human host with a MAP infection to provide a simple and rapid serological test which can diagnose patients with Crohn's disease and can aid in the selection of patients for certain antibiotic therapies. A similar system could be used for the diagnosis and selection for therapy of tuberculosis and other mycobacterial or bacterial diseases.
Resumen de: WO2025179106A1
A system or method for a combination assay of human antibodies to Mycobacterium avium subsp. paratuberculosis (MAP) and cytokines for the diagnosis of Crohn's disease, tuberculosis, and other bacterial diseases in symptomatic and asymptomatic individuals is provided herein. The system or method describes generally using a combination of human antibodies to MAP useful for the detection of a MAP infection in human blood samples and cytokines secreted by the human host with a MAP infection to provide a simple and rapid serological test which can diagnose patients with Crohn's disease and can aid in the selection of patients for certain antibiotic therapies. A similar system could be used for the diagnosis and selection for therapy of tuberculosis and other mycobacterial or bacterial diseases.
Resumen de: AU2023364180A1
Provided herein is a peptide array comprising a plurality of flagellin peptides corresponding to highly conserved peptide regions. For example, the peptide array comprises a plurality of
Resumen de: EP4607197A1
Provided is an examination method for irAE enteritis, said examination method comprising a detection step for detecting, as an indicator of ulcerous colitis-like irAE enteritis, an antibody that immunologically reacts with a fragment of, or the entirety of, integrin αvβ6 in a specimen.
Resumen de: EP4606910A1
The present invention relates to diagnostic and prognostic methods and their use in diagnosing or predicting disease progression in a subject with Ulcerative Colitis (UC). More particularly, the present invention relates to a gene expression signature and the use thereof in determining the likelihood of progression of Ulcerative Colitis in a subject, as well as compositions for the detection thereof. The invention also extends to the use of biomarkers as targets to improve the treatment of Ulcerative Colitis in patients.
Resumen de: JP2025124594A
To provide novel therapies for treating or ameliorating inflammatory bowel diseases, including ulcerative colitis and Crohn's disease, as well as for treating other autoimmune conditions.SOLUTION: The present invention relates to antibodies that specifically bind to one or both of IL27RA and gp130. The present invention further relates to bispecific antibodies that specifically bind to IL27RA and gp130. The present invention also relates to related molecules, e.g., nucleic acids encoding such antibodies or bispecific antibodies, compositions, and related methods, e.g., methods for producing and purifying such antibodies and bispecific antibodies, and their use in diagnostic and therapeutic agents.SELECTED DRAWING: Figure 1
Resumen de: CN120536298A
The invention belongs to the technical field of microorganisms, and discloses lactobacillus fermentum (L.f) LFSJ001 and application of the lactobacillus fermentum (L.f) LFSJ001 in preparation of a product for preventing or treating ulcerative colitis. The lactobacillus fermentum LFSJ001 is subjected to autonomous separation and identification. According to the application disclosed by the invention, a mouse colitis model is constructed by using DSS, and it is found that combined treatment of lactobacillus fermentum LFSJ001 and mesalazine (5-ASA) can enhance improvement of 5-ASA on colitis symptoms, including a plurality of indexes such as a disease activity index, a colon injury index and a spleen index. Therefore, the lactobacillus fermentum LFSJ001 can be used as a combined medicine of the 5-ASA, the medicine effect of the 5-ASA is enhanced, the occurrence and development of the ulcerative colitis are inhibited, the intestinal barrier is improved, and a new diagnosis and treatment direction and strategy are provided for prevention and treatment of the ulcerative colitis.
Resumen de: CN120536347A
The invention discloses a preparation method of an intestinal organ inflammation model based on inflammatory factors, and belongs to the technical field of biomedicine. The invention provides an innovative in-vitro culture method based on intestinal organs, and aims to simulate inflammatory response in inflammatory bowel disease (IBD) and influence of the inflammatory response on intestinal epithelium and stem cells. Specific inflammatory factors IL-22, IFN-gamma and TNF-alpha are introduced into an organoid culture system, an inflammatory environment related to IBD is successfully induced, and a key feature of IBD is observed: expression of a fetal-like intestine stem cell marker gene Sca-1 is remarkably increased. The model fully simulates the repair mechanism of the intestinal tract in inflammatory response. The invention discloses key effects of different inflammatory factors on intestinal epithelium functions and fetal-like intestine stem cells in a repair process, and provides a unique in-vitro platform for deeply researching a repair mechanism. The invention provides a novel in-vitro experimental platform for mechanism research, diagnosis, personalized treatment and drug screening of the inflammatory bowel disease.
Nº publicación: CN120519578A 22/08/2025
Solicitante:
GUANGZHOU FIRST PEOPLES HOSPITAL GUANGZHOU DIGESTIVE DISEASE CENTER THE FIRST PEOPLES HOSPITAL AFFIL
\u5E7F\u5DDE\u5E02\u7B2C\u4E00\u4EBA\u6C11\u533B\u9662\uFF08\u5E7F\u5DDE\u6D88\u5316\u75BE\u75C5\u4E2D\u5FC3\u3001\u5E7F\u5DDE\u533B\u79D1\u5927\u5B66\u9644\u5C5E\u5E02\u4E00\u4EBA\u6C11\u533B\u9662\u3001\u534E\u5357\u7406\u5DE5\u5927\u5B66\u9644\u5C5E\u7B2C\u4E8C\u533B\u9662\uFF09
Resumen de: CN120519578A
The invention provides an application of APOL1 in diagnosis of neonatal necrotizing enterocolitis. Research finds that compared with a control child patient, the APOL1 gene and protein expression level in NEC child patients are remarkably improved for the first time, ROC curve analysis results show that when APOL1 is used for NEC diagnosis, AUC is 0.86, and diagnosis accuracy is high. Therefore, the APOL1 can be used as a specific diagnostic marker of the NEC for assisting clinical diagnosis of the NEC. Furthermore, when the APOL1 is combined with C reactive protein, lymphocyte count (LYM) or hemoglobin level to be used for NEC diagnosis, AUC can be further improved to 0.91-0.94, and the diagnosis accuracy is further improved. The invention provides a novel specific biomarker for diagnosis of NEC, and has important clinical value for early diagnosis and early treatment of NEC.
BOPI
Sede Electrónica
